Advent of Advanced Oral Anticoagulants Drugs To Propel Global and United States Anticoagulants Drug Market

Published Date : Apr 10, 2018

Albany, New York, Apr 10, 2018 – Anticoagulants are also known as antithrombotic drugs, which help prevent the formation of blood clot or thrombus. These drugs are used to lessen the formation of clot by reducing the production of vitamin K in the liver. Anticoagulant, antiplatelet, and thrombolytic agents are several types of elements that help in clotting process. Venous thrombosis and arterial thrombosis are both treated with anticoagulant drugs. recently published report, titled, “2018-2025 Anticoagulants Drug Report on Global and United States Market, Status and Forecast, by Players, Types and Applications.” Blood clots are formed due to sticking of platelets together and the proteins in blood combine to form a solid mass. So, anticoagulants, stop platelets to stick to each other and clotting proteins as well.

The rise in geriatric population is one of the major drivers contributing to the growth of global anticoagulants market. Moreover, rise in investment in research and development activities in the pharmaceutical industry and the advent of advanced oral anticoagulants drugs have boosted the market growth as well. On the downside, strict regulations set by several government bodies obstruct the development of the global anticoagulants market. Along with it, the possibility of complications and side-effects related to the usage of oral anticoagulants also hampers the growth of the global anticoagulants market. A noticeable trend in the market is the rise in number of mergers and acquisitions and collaborations among drug manufacturing firms.

For Sample Copy, click here:

Anticoagulants are majorly segmented into warfarin, herapins, low molecular weight heparins (LMWHs), direct thrombin inhibitors (DTIs), and factor Xa inhibitors. Among these, Heparin is an injectable anticoagulant majorly utilized in hospitals for speedy anticoagulation. Low molecular weight heparins are given almost twice a day as below the skin injections to cure DVT. LMWHs are comparatively more convenient to use in place of heparins, as it can be self-administered at home, as well. Moreover, warfarin is generally recommended as part of long-term anticoagulant therapy for patients suffering from atrial fibrillation to reduce the danger of heart attack by more than 60%. The global anticoagulants market is segmented on the basis of various applications and anticoagulant drugs. The different types of anticoagulants available in the market are Dabigatran (Pradaxa), Betrixaban, Edoxaban, Eliquis (Apixaban), Rivaroxaban (Xarelto). The application segment is sub segmented into coronary artery diseases, cardiovascular diseases, cardiac arrhythmia, DVT, myocardial infarction, and heart valve replacement.

On the basis of geography, North America leads the global anticoagulants market owing to growing awareness regarding therapeutic applications of anticoagulants in illness management in the region. The U.S. holds the biggest market for anticoagulants in North America, trailed by Canada. Johnson & Johnson (US), C. H. Boehringer Sohn (Germany), Daiichi Sankyo (Japan), Roche (Switzerland), Siemens (Germany), CoaguSense (US), Bristol-Myers, Squibb (US), Pfizer (US), Portola Pharmaceuticals (US), Abbott (US), and Alere (US) are some of the key players in the global and US market.

To order report Call Toll Free: 866-997-4948 or send an email on